Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging.

Abstract:

:Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they're relatively cell-, receptor- and energy-independent, CPPs have unique advantages in facilitating drugs entry into cells. This paper briefly reviews the discovery, mechanism and classification of CPPs, and especially focuses on the specific limitations of CPPs and their potential applications for tumor-targeted delivery of biologically active molecules, imaging agents and carriers.

authors

Wang W,Abbad S,Zhang Z,Wang S,Zhou J,Lv H

doi

10.2174/1568009615666150211104524

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

337-51

issue

4

eissn

1568-0096

issn

1873-5576

pii

CCDT-EPUB-65121

journal_volume

15

pub_type

杂志文章,评审
  • Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.

    abstract:BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009618666180629150927

    authors: Cao Y,Wei Z,Li M,Wang H,Yin L,Chen D,Wang Y,Chen Y,Yuan Q,Pu X,Zong L,Duan S

    更新日期:2019-01-01 00:00:00

  • nMET, A New Target in Recurrent Cancer.

    abstract::Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-d...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160105105250

    authors: Xie Y,Istayeva S,Chen Z,Tokay T,Zhumadilov Z,Wu D,Hortelano G,Zhang J

    更新日期:2016-01-01 00:00:00

  • Bid stands at the crossroad of stress-response pathways.

    abstract::Bid, a BH3-only Bcl-2 family member, is proven to be a pivotal molecule for the regulation of tumorigenesis by its multiple functions in promoting apoptosis, survival and proliferation. Growing evidence supports that Bid has double roles with respect to stress-response. In most cases it functions in a truncated form, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791859515

    authors: Song G,Chen GG,Hu T,Lai PB

    更新日期:2010-09-01 00:00:00

  • Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase.

    abstract::Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791859443

    authors: Duverna R,Ablordeppey SY,Lamango NS

    更新日期:2010-09-01 00:00:00

  • Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

    abstract::Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043332736

    authors: Nikitakis NG,Siavash H,Sauk JJ

    更新日期:2004-12-01 00:00:00

  • Cetuximab: from bench to bedside.

    abstract::Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910790980241

    authors: Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

    更新日期:2010-02-01 00:00:00

  • Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.

    abstract::The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160603123014

    authors: Guerram M,Hamdi AM,Zhang LY,Jiang Z

    更新日期:2017-01-01 00:00:00

  • AKT signaling in regulating angiogenesis.

    abstract::AKT is a central signaling molecule in regulating cell survival, proliferation, tumor growth and angiogenesis. Upstream components of AKT signaling pathway such as PI3K, PTEN, and Ras are commonly mutated in many human cancers. Recently it is found that AKT plays an important role in regulating normal vascularization ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908783497122

    authors: Jiang BH,Liu LZ

    更新日期:2008-02-01 00:00:00

  • MicroRNAs in the pathobiology of multiple myeloma.

    abstract::MicroRNAs (miRNAs) are small non-coding RNAs that bind to the 3'untranslated region of target mRNAs and lead to translation repression or mRNA degradation, thus regulating important cell processes. MiRNA deregulation has been identified in virtually all types of cancer, and miRNA profiling has proved useful in cancer ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912802429274

    authors: Lionetti M,Agnelli L,Lombardi L,Tassone P,Neri A

    更新日期:2012-09-01 00:00:00

  • TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.

    abstract::Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009614666141028094612

    authors: Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

    更新日期:2015-01-01 00:00:00

  • WT1 as a novel target antigen for cancer immunotherapy.

    abstract::Wild-type Wilms' tumor gene WT1 is expressed at high levels not only in most of acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, but also in various types of solid tumors including lung cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for tumor specific immunot...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009023334088

    authors: Oka Y,Tsuboi A,Elisseeva OA,Udaka K,Sugiyama H

    更新日期:2002-03-01 00:00:00

  • Tubulin folding pathways: implication in the regulation of microtubule dynamics.

    abstract::As microtubules are essential in many cell functions, they have been used as a target of a variety of anticancer drugs that are grouped as stabilizing (taxanes) and destabilizing (vinca-alkaloids, colchicinoids) microtubule agents. It appears clearly now that the dynamic behaviour more than modifications of microtubul...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907783220426

    authors: Beghin A,Galmarini CM,Dumontet C

    更新日期:2007-12-01 00:00:00

  • Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.

    abstract::Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009614666140725090000

    authors: Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

    更新日期:2014-01-01 00:00:00

  • Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

    abstract::Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909789057024

    authors: Gleixner KV,Mayerhofer M,Vales A,Gruze A,Hörmann G,Cerny-Reiterer S,Lackner E,Hadzijusufovic E,Herrmann H,Iyer AK,Krauth MT,Pickl WF,Marian B,Panzer-Grümayer R,Sillaber C,Maeda H,Zielinski C,Valent P

    更新日期:2009-08-01 00:00:00

  • Understanding FOXO, new views on old transcription factors.

    abstract::FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800910791054158

    authors: Zanella F,Link W,Carnero A

    更新日期:2010-03-01 00:00:00

  • Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

    abstract:BACKGROUND AND AIM:Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patient...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911793743600

    authors: Santini D,Schiavon G,Vincenzi B,Cass CE,Vasile E,Manazza AD,Catalano V,Baldi GG,Lai R,Rizzo S,Giacobino A,Chiusa L,Caraglia M,Russo A,Mackey J,Falcone A,Tonini G

    更新日期:2011-01-01 00:00:00

  • Anti-angiogenic approaches to malignant gliomas.

    abstract::Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF mo...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912799277584

    authors: Soffietti R,Trevisan E,Bertero L,Bosa C,Ruda R

    更新日期:2012-03-01 00:00:00

  • Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

    abstract::Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800912801784839

    authors: Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

    更新日期:2012-07-01 00:00:00

  • Novel approaches to target pancreatic cancer.

    abstract::Despite remarkable progress that has been made in the recent years in the treatment of gastrointestinal tumors, in particular colorectal cancer, the prognosis of pancreatic cancer remains dismal. Five years after diagnosis almost all patients have died. At early stages of the disease surgery is the only modality to ac...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911796191079

    authors: Porzner M,Seufferlein T

    更新日期:2011-07-01 00:00:00

  • Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.

    abstract::The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666200424145622

    authors: Becker JS,Fathi AT

    更新日期:2020-01-01 00:00:00

  • The mTOR pathway: a new target in cancer therapy.

    abstract::Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal transduction from various growth factors and upstream proteins to the level of mRNA translation and ribosome biogenesis, with pivotal regulatory effects on cell cycle progression, cellular proliferation and growth, autophagy and angiogenes...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791517172

    authors: Ciuffreda L,Di Sanza C,Incani UC,Milella M

    更新日期:2010-08-01 00:00:00

  • Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

    abstract::Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009611313020008

    authors: Grunt TW,Mariani GL

    更新日期:2013-02-01 00:00:00

  • Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.

    abstract::An apparent low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors is reported; however, the molecular mechanisms have not been elucidated. Angiotensin-II (Ang-II) is well known to be associated with hypertension, as a main peptide of the renin-angiotensin system, and its ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009054629663

    authors: Uemura H,Nakaigawa N,Ishiguro H,Kubota Y

    更新日期:2005-08-01 00:00:00

  • Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

    abstract::Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909788166619

    authors: Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

    更新日期:2009-05-01 00:00:00

  • Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

    abstract::Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009618666181010091246

    authors: Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

    更新日期:2019-01-01 00:00:00

  • The clinical applications of heat shock protein inhibitors in cancer - present and future.

    abstract::The potential clinical applications of the prototype first-in-class Hsp90 inhibitor 17AAG and other emerging Hsp90 drugs are very exciting. Rigorously planned and executed clinical trials, incorporating measurement of appropriate biomarkers and pharmocodynamic endpoints are critical for selecting the optimal dose and ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009033481813

    authors: Banerji U,Judson I,Workman P

    更新日期:2003-10-01 00:00:00

  • Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.

    abstract:BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009617666170630143931

    authors: Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

    更新日期:2018-01-01 00:00:00

  • A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

    abstract::Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800911795656001

    authors: Cai T,Li X,Ding J,Luo W,Li J,Huang C

    更新日期:2011-06-01 00:00:00

  • The SCF-type E3 Ubiquitin Ligases as Cancer Targets.

    abstract::The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin-proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-a...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666151112122231

    authors: Kitagawa K,Kitagawa M

    更新日期:2016-01-01 00:00:00

  • Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment.

    abstract::One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666171114143330

    authors: Lisiak N,Toton E,Rybczynska M

    更新日期:2018-01-01 00:00:00